SRRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sierra Oncology's share price is $54.99. Sierra Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $0.00. Hence, Sierra Oncology's PS Ratio for today is .
The historical rank and industry rank for Sierra Oncology's PS Ratio or its related term are showing as below:
During the past 9 years, Sierra Oncology's highest PS Ratio was 3055.00. The lowest was 0.00. And the median was 1134.50.
Sierra Oncology's Revenue per Sharefor the three months ended in Mar. 2022 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $0.00.
During the past 12 months, the average Revenue per Share Growth Rate of Sierra Oncology was -100.00% per year.
The historical data trend for Sierra Oncology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sierra Oncology Annual Data | |||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||||||
PS Ratio | Get a 7-Day Free Trial | - | - | - | 552.76 | - |
Sierra Oncology Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
PS Ratio | Get a 7-Day Free Trial | 615.36 | 695.36 | 1,217.78 | - | - |
For the Biotechnology subindustry, Sierra Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sierra Oncology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sierra Oncology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sierra Oncology's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 54.99 | / | 0 | |
= |
Sierra Oncology's Share Price of today is $54.99.
Sierra Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
Sierra Oncology (NAS:SRRA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of Sierra Oncology's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivo Opportunity Fund Holdings, L.p. | director, 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
William D. Turner | officer: Chief Reg & Tech Ops Officer | C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 |
Mary Christina Thomson | officer: General Counsel | C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 |
Joshua Richardson | director, 10 percent owner | C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
Longitude Prime Fund, L.p. | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Longitude Prime Partners, Llc | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Gaurav Aggarwal | director, 10 percent owner | C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Vivo Opportunity Fund, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Andrew Sinclair | director | C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Craig A Collard | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Georgia Erbez | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Christy J. Oliger | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
From GuruFocus
By Business Wire Business Wire • 04-13-2022
By Business Wire Business Wire • 06-17-2022
By Business Wire Business Wire • 02-18-2022
By Business Wire Business Wire • 01-18-2022
By Business Wire Business Wire • 01-27-2022
By Business Wire Business Wire • 05-05-2022
By Business Wire Business Wire • 02-04-2022
By Business Wire Business Wire • 02-03-2022
By Business Wire Business Wire • 05-02-2022
By Business Wire Business Wire • 01-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.